JP2016540759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540759A5 JP2016540759A5 JP2016535047A JP2016535047A JP2016540759A5 JP 2016540759 A5 JP2016540759 A5 JP 2016540759A5 JP 2016535047 A JP2016535047 A JP 2016535047A JP 2016535047 A JP2016535047 A JP 2016535047A JP 2016540759 A5 JP2016540759 A5 JP 2016540759A5
- Authority
- JP
- Japan
- Prior art keywords
- agents
- subject
- assay
- cell cycle
- timp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 26
- 238000003556 assay Methods 0.000 claims 22
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims 10
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 claims 10
- 210000001124 body fluid Anatomy 0.000 claims 6
- 230000006370 G0 arrest Effects 0.000 claims 5
- 230000037057 G1 phase arrest Effects 0.000 claims 5
- 239000010839 body fluid Substances 0.000 claims 5
- 208000033626 Renal failure acute Diseases 0.000 claims 4
- 201000011040 acute kidney failure Diseases 0.000 claims 4
- 239000000090 biomarker Substances 0.000 claims 4
- 230000006369 cell cycle progression Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 210000002919 epithelial cell Anatomy 0.000 claims 3
- 210000001985 kidney epithelial cell Anatomy 0.000 claims 3
- 229930105110 Cyclosporin A Natural products 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 claims 1
- QEEBRPGZBVVINN-UHFFFAOYSA-N Desacetyl-bufotalin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C1(O)CCC2C=1C=CC(=O)OC=1 QEEBRPGZBVVINN-UHFFFAOYSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims 1
- -1 NC381 Chemical compound 0.000 claims 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims 1
- 229950010817 alvocidib Drugs 0.000 claims 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims 1
- 229960004991 artesunate Drugs 0.000 claims 1
- QEEBRPGZBVVINN-BMPKRDENSA-N bufalin Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)CC[C@@]32C)C=CC(=O)OC=1 QEEBRPGZBVVINN-BMPKRDENSA-N 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000025084 cell cycle arrest Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 229960002404 palifermin Drugs 0.000 claims 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 claims 1
- 238000012959 renal replacement therapy Methods 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 229960004066 trametinib Drugs 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911406P | 2013-12-03 | 2013-12-03 | |
| US61/911,406 | 2013-12-03 | ||
| PCT/US2014/068337 WO2015084939A1 (en) | 2013-12-03 | 2014-12-03 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202233A Division JP7068256B2 (ja) | 2013-12-03 | 2019-11-07 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016540759A JP2016540759A (ja) | 2016-12-28 |
| JP2016540759A5 true JP2016540759A5 (https=) | 2018-01-18 |
Family
ID=53274065
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016535047A Pending JP2016540759A (ja) | 2013-12-03 | 2014-12-03 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| JP2019202233A Active JP7068256B2 (ja) | 2013-12-03 | 2019-11-07 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202233A Active JP7068256B2 (ja) | 2013-12-03 | 2019-11-07 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10300108B2 (https=) |
| EP (1) | EP3077819A4 (https=) |
| JP (2) | JP2016540759A (https=) |
| CN (2) | CN110007084B (https=) |
| WO (1) | WO2015084939A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2836218T3 (es) | 2008-10-21 | 2021-06-24 | Astute Medical Inc | Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| WO2011075744A1 (en) | 2009-12-20 | 2011-06-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US10935548B2 (en) | 2011-12-08 | 2021-03-02 | Astute Medical, Inc. | Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2 |
| EP3361255B1 (en) | 2013-01-17 | 2020-03-11 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN110007084B (zh) | 2013-12-03 | 2022-11-18 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| US11243202B2 (en) | 2015-04-09 | 2022-02-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| BR112019005539A2 (pt) * | 2016-10-05 | 2019-06-18 | Mitobridge, Inc. | métodos de tratamento de lesão renal aguda |
| WO2018081447A1 (en) | 2016-10-26 | 2018-05-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compositions and methods for reducing the rick of radiocontrast-induced nephropathy |
| CN110352073A (zh) * | 2016-10-28 | 2019-10-18 | 机敏医药股份有限公司 | 针对timp-2的抗体用于改善肾功能的用途 |
| CN110431422A (zh) | 2017-02-06 | 2019-11-08 | 机敏医药股份有限公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| CN110709103B (zh) | 2017-04-05 | 2024-02-02 | 机敏医药股份有限公司 | 用于生物学样品中具有改善的性能的timp2的测定法 |
| JP2020524714A (ja) | 2017-06-23 | 2020-08-20 | エーケーアイ・セラピューティクス・エーぺーエス | 急性腎障害の予防及び治療のための組成物 |
| IT201900001365A1 (it) * | 2019-01-30 | 2020-07-30 | Torino Politecnico | Sistema di monitoraggio e previsione della diuresi per il calcolo del rischio di insufficienza renale, e relativo metodo |
| CA3152922A1 (en) * | 2019-10-12 | 2021-04-15 | Michael Peel | Treatment and prevention of nephrotoxin-induced kidney injuries |
| CN112316150B (zh) * | 2020-12-04 | 2023-04-28 | 深圳市中医院 | 一种用于预防或治疗代谢或损伤相关疾病的药物组合物 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| AU1772992A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| JP3290988B2 (ja) | 1991-04-11 | 2002-06-10 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | 多重リガンドを同時検出する新規接合体及び検定法 |
| US5324634A (en) | 1992-03-31 | 1994-06-28 | The Research Foundation Of State University Of New York | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6140045A (en) | 1995-03-10 | 2000-10-31 | Meso Scale Technologies | Multi-array, multi-specific electrochemiluminescence testing |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| EP1151101A4 (en) | 1998-12-18 | 2002-10-09 | Human Genome Sciences Inc | PROSTACYCLIN-STIMULATING FACTOR-2 |
| ATE376187T1 (de) | 1998-12-21 | 2007-11-15 | Univ Monash | Nachweis von erkrankungen der nieren und behandlung |
| US20040126767A1 (en) | 2002-12-27 | 2004-07-01 | Biosite Incorporated | Method and system for disease detection using marker combinations |
| US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| JP2003081838A (ja) | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
| GB0130557D0 (en) | 2001-12-20 | 2002-02-06 | Serono Internat S A | Proteins |
| US7138230B2 (en) | 2002-12-06 | 2006-11-21 | Renovar, Inc. | Systems and methods for characterizing kidney diseases |
| US7560244B2 (en) | 2003-06-04 | 2009-07-14 | Joslin Diabetes Center, Inc. | Method of evaluating a subject for risk or predisposition of reduced renal function over time |
| US20050084880A1 (en) | 2003-07-11 | 2005-04-21 | Ronald Duman | Systems and methods for diagnosing & treating psychological and behavioral conditions |
| NZ588323A (en) | 2003-07-17 | 2012-04-27 | Pacific Edge Biotechnology Ltd | Markers for the detection of gastric cancer |
| US20080038192A1 (en) | 2004-07-19 | 2008-02-14 | Neurochem Inc. | Diagnostic Methods Of Multiple Organ Amyloidosis |
| WO2006010529A1 (en) | 2004-07-28 | 2006-02-02 | F. Hoffmann-La Roche Ag | Timp-2 as target/marker of beta cell failure |
| US20080090759A1 (en) | 2004-08-30 | 2008-04-17 | Robert Kokenyesi | Methods and kits for predicting risk for preterm labor |
| ITVI20050059A1 (it) | 2005-03-04 | 2006-09-05 | Consorzio Per Gli Studi Universitari In Verona | Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali |
| EP1871909A4 (en) | 2005-03-31 | 2010-05-19 | Univ Leland Stanford Junior | COMPOSITIONS AND METHODS OF DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDER |
| US20070087387A1 (en) | 2005-04-21 | 2007-04-19 | Prasad Devarajan | Method for the Early Detection of Renal Disease Using Proteomics |
| EP1915614A4 (en) | 2005-07-21 | 2009-03-25 | Univ Johns Hopkins | METHOD FOR DETECTING AND TREATING AN ACUTE KIDNEY INJURY |
| EP1757940A1 (en) | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| US20080133141A1 (en) | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| WO2007124331A2 (en) | 2006-04-19 | 2007-11-01 | Virginia Commonwealth University | Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors |
| US7662578B2 (en) | 2006-04-21 | 2010-02-16 | Children's Hospital Medical Center | Method and kit for the early detection of impaired renal status |
| US20080090765A1 (en) * | 2006-05-25 | 2008-04-17 | The Trustees Of Columbia University In The City Of New York | Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage |
| GB0617429D0 (en) | 2006-09-05 | 2006-10-18 | Electrophoretics Ltd | Markers of renal transplant rejection and renal damage |
| WO2008067065A2 (en) | 2006-10-19 | 2008-06-05 | Shiv Srivastava | Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers |
| JP2010517023A (ja) | 2007-01-25 | 2010-05-20 | エフ．ホフマン−ラ ロシュ アーゲー | 心不全の評価におけるｉｇｆｂｐ−７の使用 |
| CN101910845A (zh) | 2007-11-15 | 2010-12-08 | 比奥波托诊断股份公司 | 个体分子形式的生物标志的诊断用途 |
| US8592925B2 (en) | 2008-01-11 | 2013-11-26 | Seiko Epson Corporation | Functional device with functional structure of a microelectromechanical system disposed in a cavity of a substrate, and manufacturing method thereof |
| JP2012501456A (ja) | 2008-08-28 | 2012-01-19 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| EP2324354B1 (en) | 2008-08-29 | 2014-07-16 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
| US20110256560A1 (en) | 2008-10-20 | 2011-10-20 | University Health Network | Methods and compositions for the detection of ovarian cancer |
| ES2836218T3 (es) | 2008-10-21 | 2021-06-24 | Astute Medical Inc | Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| EP2913676A1 (en) | 2008-11-10 | 2015-09-02 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN102369293B (zh) * | 2009-02-06 | 2014-05-28 | 阿斯图特医药公司 | 肾损伤和肾衰竭的诊断及预后 |
| US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US8313949B2 (en) | 2009-04-16 | 2012-11-20 | Nextcea Inc. | Detecting phospholipidosis and diagnosing lysosomal storage disorders |
| US8974491B2 (en) | 2009-06-23 | 2015-03-10 | Infarct Reduction Technologies Inc. | Methods for adaptive limb occlusion |
| NZ598035A (en) | 2009-08-07 | 2014-06-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20120315649A1 (en) | 2009-08-28 | 2012-12-13 | Astute Medical ,Inc. a corporation | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CA2774223A1 (en) | 2009-09-21 | 2011-03-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20120156701A1 (en) * | 2009-12-20 | 2012-06-21 | Joseph Anderberg | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2011075744A1 (en) * | 2009-12-20 | 2011-06-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2011213684B2 (en) | 2010-02-05 | 2014-11-20 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ701807A (en) | 2010-02-26 | 2015-05-29 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20130210043A1 (en) | 2010-06-23 | 2013-08-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| PT2748605T (pt) | 2011-08-26 | 2019-05-03 | Astute Medical Inc | Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal |
| US10935548B2 (en) | 2011-12-08 | 2021-03-02 | Astute Medical, Inc. | Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2 |
| EP2923204A1 (en) | 2012-10-31 | 2015-09-30 | Astute Medical, Inc. | Quantitative lateral flow assay |
| EP3361255B1 (en) | 2013-01-17 | 2020-03-11 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| TWI558403B (zh) | 2013-06-04 | 2016-11-21 | 中央研究院 | 富含半乳糖脂之植物萃取物及其用途 |
| US20160146832A1 (en) | 2013-06-05 | 2016-05-26 | Lakhmir S. Chawla | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| KR20160039682A (ko) | 2013-08-07 | 2016-04-11 | 아스튜트 메디컬 인코포레이티드 | 생물학적 샘플에서 개선된 성능을 가지는 timp2에 대한 검정 |
| JP2017501211A (ja) | 2013-11-06 | 2017-01-12 | アスチュート メディカル，インコーポレイテッド | 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ |
| CN110007084B (zh) | 2013-12-03 | 2022-11-18 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| US11243202B2 (en) | 2015-04-09 | 2022-02-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN108139409B (zh) | 2015-10-08 | 2020-07-24 | 豪夫迈·罗氏有限公司 | 当在外科手术之前测量时用于预测aki的风险的igfbp7 |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| CN110352073A (zh) | 2016-10-28 | 2019-10-18 | 机敏医药股份有限公司 | 针对timp-2的抗体用于改善肾功能的用途 |
| CN110431422A (zh) | 2017-02-06 | 2019-11-08 | 机敏医药股份有限公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| CN110709103B (zh) | 2017-04-05 | 2024-02-02 | 机敏医药股份有限公司 | 用于生物学样品中具有改善的性能的timp2的测定法 |
| CN110753700A (zh) | 2017-05-07 | 2020-02-04 | 机敏医药股份有限公司 | 胰岛素样生长因子结合蛋白7和金属蛋白酶2组织抑制物在肾脏替代疗法的管理中的用途 |
-
2014
- 2014-12-03 CN CN201910275935.3A patent/CN110007084B/zh active Active
- 2014-12-03 JP JP2016535047A patent/JP2016540759A/ja active Pending
- 2014-12-03 CN CN201480073639.0A patent/CN105917229B/zh active Active
- 2014-12-03 WO PCT/US2014/068337 patent/WO2015084939A1/en not_active Ceased
- 2014-12-03 US US15/101,118 patent/US10300108B2/en active Active
- 2014-12-03 EP EP14868424.4A patent/EP3077819A4/en active Pending
-
2019
- 2019-05-24 US US16/422,520 patent/US11229676B2/en active Active
- 2019-11-07 JP JP2019202233A patent/JP7068256B2/ja active Active
-
2022
- 2022-01-24 US US17/582,999 patent/US20220143133A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540759A5 (https=) | ||
| Deng et al. | STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib | |
| Martin et al. | Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| Yao et al. | Effect of chronic intermittent hypoxia on triglyceride uptake in different tissues | |
| JP2019502689A5 (https=) | ||
| Laragione et al. | The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion | |
| Zhang et al. | Triptolide protects rat heart against pressure overload-induced cardiac fibrosis | |
| JP2017531673A5 (https=) | ||
| JP2014532726A5 (https=) | ||
| Takakuta et al. | Renoprotective properties of pirfenidone in subtotally nephrectomized rats | |
| Yang et al. | Comparison of angiotensin-(1–7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice | |
| EA201990664A1 (ru) | Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| Mohamed et al. | Role of nitric oxide and KATP channel in the protective effect mediated by nicorandil in bile duct ligation-induced liver fibrosis in rats | |
| WO2020207165A1 (zh) | 治疗脉管畸形的化合物 | |
| Faltlhauser et al. | Use of hemoadsorption in a case of severe hepatic failure and hyperbilirubinemia | |
| Monk et al. | Incidence and management of edema associated with trebananib (AMG 386) | |
| Zou et al. | The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo | |
| Wang et al. | Beneficial therapeutic effects of hemoperfusion in the treatment of severe Stevens-Johnson syndrome/toxic epidermal necrolysis: preliminary results. | |
| Chan et al. | Cardiorenal syndrome: the clinical cardiologists’ perspective | |
| Schwendt et al. | Acute exposure to phthalates during recovery from a myocardial infarction induces greater inflammasome activation in male C57bl/6N mice | |
| Yang et al. | Expression of profibrotic genes in a murine remnant kidney model | |
| Lee et al. | Comparative portal hypotensive effects as propranolol of vitamin D 3 treatment by decreasing intrahepatic resistance in cirrhotic rats | |
| Amato et al. | Molecular-targeted therapy for renal cell carcinoma |